TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10905488

Group type: EXPERIMENTAL
Intervention: IGF-I treatment (40 microg x kg(‐1) x day(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8621136

Group type: EXPERIMENTAL
Intervention: Insulinlike growth factor I (IGF‐I)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Insulinlike growth factor binding protein 3 (IGFBP‐3)
Number of subjects: 337
Study: 1417188

Group type: EXPERIMENTAL
Intervention: Diet plus partial ileal bypass surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: Diet-control group
Number of subjects: 78
Study: 3899841

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 30741682

Group type: EXPERIMENTAL
Intervention: Cerebral amyloid-β (Aβ) deposition measured by 11C Pittsburgh compound B (PIB) PET scan
Number of subjects: 30
Study: 29626614

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) intervention (3.6‐11.6 g), 3 times per week for 6 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Swimming training only (Control group)
Number of subjects: 51
Study: 26250477

Group type: EXPERIMENTAL
Intervention: SRP + DL (scaling, root planing and laser irradiation of periodontal pockets)
Number of subjects: 32

Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 32
Study: 24984928

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine with epinephrine (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Group 3)
Number of subjects: 60
Study: 22326721

Group type: EXPERIMENTAL
Intervention: RMGI without biofilm accumulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RMGI with biofilm accumulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CR without biofilm accumulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CR with biofilm accumulation
Number of subjects: 10
Study: 20213467

Group type: EXPERIMENTAL
Intervention: IPS (16 cmH2O) + PEEP (5 cmH2O)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 21
Study: 18394965

Group type: EXPERIMENTAL
Intervention: Transcranial sonography (TCS)
Number of subjects: 60
Study: 16521847

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte (CHOv) solution (7 mL/kg) ingested at 0 and 45 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte (CHOf) solution (7 mL/kg) ingested in smaller volumes at 0, 15, 30, 45, 60, and 75 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA) solution (7 mL/kg) ingested at 0 and 45 min
Number of subjects: 12
Study: 11867969

Group type: EXPERIMENTAL
Intervention: Avena sativa extract
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Avena Rhealba extract
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle (petrolatum ointment)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 12
Study: 10468696

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.d.
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Alosetron 2 mg b.d.
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Alosetron 4 mg b.d.
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Alosetron 8 mg b.d.
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 7784854

Group type: EXPERIMENTAL
Intervention: Immediate written consent from parents
Number of subjects: 517

Group type: COMPARATOR
Intervention: Delayed response (after reminders) from parents
Number of subjects: 517
Study: 1693087

Group type: EXPERIMENTAL
Intervention: Animated display of transformations
Number of subjects: 108

Group type: COMPARATOR
Intervention: Diagram sheet (Control Group 1)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Computer-presented display with ten discrete stages (Control Group 2)
Number of subjects: 108
Study: 345889

Group type: EXPERIMENTAL
Intervention: Sustained release theophylline preparation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 31101570

Group type: COMPARATOR
Intervention: MCO plans for prostate only
Number of subjects: 66

Group type: COMPARATOR
Intervention: MCO plans for whole pelvis
Number of subjects: 66

Group type: COMPARATOR
Intervention: MCO plans for lung
Number of subjects: 66

Group type: COMPARATOR
Intervention: MCO plans for pancreas
Number of subjects: 66

Group type: COMPARATOR
Intervention: MCO plans for head and neck
Number of subjects: 66
Study: 30739369

Group type: EXPERIMENTAL
Intervention: Topical gaseous ozone applied into periodontal pockets twice a week for 2 weeks during active periodontal therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control sites (no ozone therapy)
Number of subjects: 36
Study: 29029258

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo-Acupuncture
Number of subjects: 76
Study: 25370147

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU/1 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24835171

Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 0
Study: 22713551

Group type: EXPERIMENTAL
Intervention: CaP-hybridized tendon graft
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 64
Study: 19635648

Group type: EXPERIMENTAL
Intervention: Inability to stop smoking
Number of subjects: 367
Study: 17613399

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg on Day 0 and Day 4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG, 2.5 mg/kg/day for 3 to 5 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 80
Study: 15255444

Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush
Number of subjects: 26

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 26
Study: 12389081

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 9438629

Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 115

Group type: COMPARATOR
Intervention: IPOM
Number of subjects: 115
Study: 8130287

Group type: EXPERIMENTAL
Intervention: Group physical therapy (weekly for 9 months)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Home exercises (unsupervised)
Number of subjects: 144
Study: 2446574

Group type: EXPERIMENTAL
Intervention: Aprotinin (high doses to achieve plasma concentrations of more than 150 kallikrein inactivator units per milliliter)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 11
Study: 31209158

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program with physician training, assessment, and feedback; intervention details include didactic instruction and video vignettes modeling effective communication.
Number of subjects: 77

Group type: COMPARATOR
Intervention: Wait-list control arm; no specific intervention mentioned.
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program (excluding physicians with poor data quality).
Number of subjects: 77
Study: 29619453

Group type: EXPERIMENTAL
Intervention: Supervised exposure to one standard erythemal dose (SED; 100 J m‐2) of solar UV radiation three days per week for three weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no supervised sun exposure)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Supervised exposure to solar UV radiation
Number of subjects: 36
Study: 26952713

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 321
Study: 25033585

Group type: EXPERIMENTAL
Intervention: Placement of fixed orthodontic appliances (Group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Removal of fixed orthodontic appliances (Group B)
Number of subjects: 33
Study: 22054904

Group type: EXPERIMENTAL
Intervention: Unipolar hemostasis
Number of subjects: 113

Group type: COMPARATOR
Intervention: Bipolar hemostasis
Number of subjects: 113
Study: 20199828

Group type: EXPERIMENTAL
Intervention: Energy-protein supplements (40 g of protein and 400 kcal per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study: 17469678

Group type: EXPERIMENTAL
Intervention: Newer disease-modifying approaches such as immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research participation
Number of subjects: 0
Study: 15670038

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 98

Group type: COMPARATOR
Intervention: no GPIIb-IIIa antagonist (control)
Number of subjects: 98
Study: 14959726

Group type: EXPERIMENTAL
Intervention: Self-management education programs for children with asthma
Number of subjects: 0
Study: 11034258

Group type: EXPERIMENTAL
Intervention: Sirolimus (0.3 mg/m2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sirolimus (1 mg/m2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sirolimus (3 mg/m2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sirolimus (5 mg/m2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sirolimus (8 mg/m2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 45
Study: 8883008

Group type: EXPERIMENTAL
Intervention: Assessment in Frontal Plane (FP) for shoulder internal rotation (IR) and external rotation (ER)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Assessment in Scapular Plane (SP) for shoulder internal rotation (IR) and external rotation (ER)
Number of subjects: 20
Study: 1606397

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 10
Study: 4022696

Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study: 3675055

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1 day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Doxycycline (5 days)
Number of subjects: 120
Study: 31769897

Group type: EXPERIMENTAL
Intervention: Azithromycin-doxycycline
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Azithromycin-rifampin
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 240
Study: 31184810

Group type: EXPERIMENTAL
Intervention: Predictive score model for mortality risk in dementia patients
Number of subjects: 6556
Study: 27741216

Group type: EXPERIMENTAL
Intervention: RT + CR
Number of subjects: 126

Group type: COMPARATOR
Intervention: RT
Number of subjects: 126
Study: 26512775

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (OMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol with sequential OMP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P4 (progesterone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol/OMP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CEE/E/E2+cyclic OMP at 200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CEE/E/E2+MPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OMP with conjugated equine estrogen (CEE)/estrogen (E)/E2
Number of subjects: 0
Study: 23796316

Group type: EXPERIMENTAL
Intervention: Pragmatic rehabilitation
Number of subjects: 195

Group type: COMPARATOR
Intervention: General practitioner (GP) treatment as usual
Number of subjects: 195
Study: 22403989

Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Pro‐Relief (8.0% arginine, calcium carbonate, 1450 ppm fluoride)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sensodyne Rapid Relief (8% strontium acetate, 1040 ppm fluoride)
Number of subjects: 121
Study: 19375907

Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 4198

Group type: COMPARATOR
Intervention: Men with a family history of prostate cancer
Number of subjects: 4198

Group type: COMPARATOR
Intervention: Men with raised PSA of 10-<20ng/ml
Number of subjects: 4198

Group type: COMPARATOR
Intervention: Change in anxiety scores since the initial PSA test
Number of subjects: 4198
Study: 16808019

Group type: EXPERIMENTAL
Intervention: Traditional up-dosing treatment schedule
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-up-dosing treatment schedule
Number of subjects: 20
Study: 16646877

Group type: EXPERIMENTAL
Intervention: Recreational Music-making (RMM) protocol, 6 sessions focusing on group support and stress reduction
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Recreational Music-making (RMM) protocol
Number of subjects: 75
Study: 10667623

Group type: EXPERIMENTAL
Intervention: Oral support (cheek and jaw support)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No oral support (control group)
Number of subjects: 20
Study: 9049690

Group type: EXPERIMENTAL
Intervention: Tamoxifen administered during the luteal phase of the menstrual cycle
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no tamoxifen treatment)
Number of subjects: 35
Study: 8447209

Group type: EXPERIMENTAL
Intervention: Doxapram 1.8 mg.kg‐1.h‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3663580

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (728 mg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78

Group type: COMPARATOR
Intervention: alpha-tocopherol or placebo
Number of subjects: 78
Study: 28324920

Group type: EXPERIMENTAL
Intervention: Genexol-PM 260 mg/m2 plus carboplatin
Number of subjects: 131

Group type: COMPARATOR
Intervention: Genexol 175 mg/m2 plus carboplatin
Number of subjects: 131
Study: 28404108

Group type: EXPERIMENTAL
Intervention: 12 weeks of treatment with ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin dosed twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 16 weeks of treatment with ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin dosed twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 12 weeks of treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 16 weeks of treatment
Number of subjects: 120
Study: 25245352

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Adolescents (DBT-A)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 77
Study: 22152121

Group type: EXPERIMENTAL
Intervention: Family Motivational Intervention (FMI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine Family Support (RFS)
Number of subjects: 75
Study: 21107104

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard management (STD)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups (ANH and STD)
Number of subjects: 130
Study: 18245406

Group type: EXPERIMENTAL
Intervention: 24% oral sucrose and pacifier
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sterile water control solution
Number of subjects: 100
Study: 15789278

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp30)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Biphasic human insulin (BHI30)
Number of subjects: 12
Study: 12887149

Group type: EXPERIMENTAL
Intervention: Probing with a dental explorer on one side of the lesion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-probed side of the lesion
Number of subjects: 10
Study: 10355516

Group type: EXPERIMENTAL
Intervention: Rebamipide (oral, 300 mg/day for 3 weeks starting 1 week before TAE)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Non-rebamipide group
Number of subjects: 73
Study: 7794594

Group type: EXPERIMENTAL
Intervention: Day treatment with ambulatory and domiciliary care
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 70
Study: 2200821

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 25 micrograms b.i.d.
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms b.i.d.
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 400 micrograms b.i.d.
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 7023307

Group type: EXPERIMENTAL
Intervention: Chenodiol 750 mg/d
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Chenodiol 375 mg/d
Number of subjects: 916

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study: 31683467

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg for 15 min before incision, followed by 0.3‐0.5 μg/(kg·h) till the end of the operation)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study: 29595640

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 90
Study: 27661399

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) mixed with orange juice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) mixed with yogurt
Number of subjects: 30
Study: 24374288

Group type: EXPERIMENTAL
Intervention: Resistance-type exercise training with protein supplementation (2×15 g daily)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Resistance-type exercise training without protein supplementation
Number of subjects: 127

Group type: COMPARATOR
Intervention: No exercise program (Control)
Number of subjects: 127
Study: 22616830

Group type: EXPERIMENTAL
Intervention: DrotAA (24 μg/kg/hour) for 96 hours
Number of subjects: 1697

Group type: COMPARATOR
Intervention: Placebo for 96 hours
Number of subjects: 1697

Group type: EXPERIMENTAL
Intervention: DrotAA (24 μg/kg/hour) for 96 hours in patients with severe protein C deficiency
Number of subjects: 1697

Group type: COMPARATOR
Intervention: Placebo for 96 hours in patients with severe protein C deficiency
Number of subjects: 1697
Study: 20805258

Group type: EXPERIMENTAL
Intervention: Glulisine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 180
Study: 17634053

Group type: EXPERIMENTAL
Intervention: Treatment Optimization Program (TOP) tool
Number of subjects: 2573

Group type: COMPARATOR
Intervention: Usual ED management (non-TOP)
Number of subjects: 2573

Group type: EXPERIMENTAL
Intervention: TOP tool (video and brochure)
Number of subjects: 2573

Group type: EXPERIMENTAL
Intervention: TOP tool usage by physicians
Number of subjects: 2573
Study: 16372518

Group type: EXPERIMENTAL
Intervention: Zinc gluconate (20 mg metal zinc)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zinc oxide (17.4 mg metal zinc)
Number of subjects: 12
Study: 11942448

Group type: EXPERIMENTAL
Intervention: Telephone consultations
Number of subjects: 388

Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 388
Study: 9657654

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1600 microg daily for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo followed by budesonide
Number of subjects: 30
Study: 7814824

Group type: EXPERIMENTAL
Intervention: Eliprodil 30 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Midazolam 15 mg (positive control)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2517696

Group type: EXPERIMENTAL
Intervention: Bone mineral content in the distal forearm by single photon (125I) absorptiometry
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bone mineral content and bone mineral density of the lumbar spine measured by dual photon (153Gd) absorptiometry
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Total body bone mineral and total body bone density measured by dual photon (153Gd) absorptiometry
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Forearm scanner
Number of subjects: 118

Group type: COMPARATOR
Intervention: Spine scanner
Number of subjects: 118
Study: 30229939

Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (7 DU)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (12 DU)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 27045369

Group type: EXPERIMENTAL
Intervention: Early weightbearing (weightbearing and ROM at 2 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Late weightbearing (nonweightbearing and cast immobilization for 6 weeks)
Number of subjects: 110
Study: 24961880

Group type: EXPERIMENTAL
Intervention: High-dose α-tocopherol supplementation
Number of subjects: 1746

Group type: COMPARATOR
Intervention: Placebo arm (control)
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: Selenomethionine supplementation
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: High-grade prostate cancer (Gleason grade 7-10) with α-tocopherol
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: High-grade prostate cancer (Gleason grade 7-10) with selenomethionine
Number of subjects: 1746
Study: 22770920

Group type: EXPERIMENTAL
Intervention: 1200mg oral gabapentin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20109575

Group type: EXPERIMENTAL
Intervention: Methylene blue 1 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methylene blue 3 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methylene blue 7 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methylene blue (all doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methylene blue (high doses)
Number of subjects: 15
Study: 18664347

Group type: EXPERIMENTAL
Intervention: Tanreqing injection (20 ml, once daily for 10 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride injection (15 mg, twice daily for 10 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tanreqing injection
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride injection
Number of subjects: 90